A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease

Trial Profile

A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2017

At a glance

  • Drugs TAK 117 (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 10 May 2017 Results (n=71) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 04 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2015 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top